Startup Deep Dive : MFine — how a $48 million virtual hospital became a diagnostics merger

In the year to March 2022, the company behind MFine spent ₹258 crore ($26.9 million) to book about ₹50 crore of operating revenue — roughly ₹5.11 of cost for every rupee earned, as per its filings with the Registrar of Companies. Six months earlier it had raised $48 million and told the market it was building “India’s largest virtual hospital.”

By May 2022 the same company had laid off more than half its staff, and by July 2022 it had folded its consumer telehealth business into a joint venture with a diagnostics group. This is the story of how one of India’s best-funded online-doctor apps — started by the people who built Myntra — ran into the wall between a good product and a working business, and what it did to survive.

Quick facts

What they do

MFine is an AI-assisted telehealth platform: patients open an app, describe symptoms, and are connected to a doctor for a video or chat consultation, with an AI layer that triages and structures the case before a human sees it. Around that core it built the full loop of digital primary care.

• Doctor teleconsultations across primary, secondary and chronic care, with an AI system the company said could triage over 1,200 common conditions, including diabetes and arthritis (company statement, 2019).
• At-home diagnostic lab tests and radiology, positioned as the highest-value part of the funnel.
• E-pharmacy and medicine delivery, plus dental and vision services.
• Care plans and chronic-condition management subscriptions for consumers.
• Corporate health subscriptions sold to employers as a benefit.

The stated ambition, repeated in its 2021 funding release, was to be “India’s largest virtual hospital” — a doctor network delivered through software rather than buildings.

The origin

MFine was founded in February 2017 in Bengaluru by Ashutosh Lawania and Prasad Kompalli. Both came from Myntra: Lawania was a Myntra co-founder, and Kompalli had run a business at the fashion retailer after it was absorbed into Flipkart. They were joined by other Myntra alumni, including Ajit Narayanan, a former chief technology officer, and Arjun Choudhary, a former head of growth marketing.

The founding insight was that India’s shortage was not of demand for doctors but of doctors’ time and reach. Good specialists were concentrated in a few large hospitals in a few cities. If software could handle the repetitive parts of a consultation — history-taking, triage, structuring symptoms into a usable case file — one doctor could see far more patients, and a patient in a small town could reach a specialist without travelling. MFine partnered with hospitals and their doctors rather than building its own clinics, and put an AI triage layer in front to make each consultation faster. It was an e-commerce team’s answer to a healthcare problem: treat the consultation as a funnel, remove friction, and scale the supply of doctor-minutes.

The struggle years

The model worked as a product and struggled as a business. The gap between what MFine earned and what it spent to grow was wide, and it widened before it closed.

• In FY20 the operating company, Novocura Tech, earned about ₹5.12 crore and lost ₹99.35 crore (RoC filing).
• In FY21, operating revenue grew 152% to ₹12.9 crore, but the loss barely moved, rising 3.4% to ₹102.7 crore (RoC filing). Revenue was tiny relative to burn.
• In FY22, revenue jumped to about ₹50 crore, but total expenses hit ₹258 crore and the net loss doubled to ₹205.89 crore. Advertising and promotion alone was ₹133.24 crore — 51.6% of all costs (Entrackr, on RoC filings).
• On a unit basis in FY22, the company spent ₹5.11 for every rupee of operating income it booked (Entrackr).

The COVID period was a demand tailwind — teleconsultations surged when clinics were hard to reach — but it also encouraged heavy spending to capture users while the moment lasted. When the funding climate turned in early 2022, that spending became the problem. On 21 May 2022, MFine laid off more than half its workforce — reported at over 50%, and by some accounts close to 70% — of a team that LinkedIn data put at over 500 people, citing the need to reduce burn and extend runway (Entrackr). The co-founders did not comment publicly at the time.

The turning point

The single event that reset MFine was not a fundraise but a merger. On 11 July 2022, MFine announced it was combining its business with the diagnostics arm of LifeCell International, a Chennai-based group founded in 2004 that runs a stem-cell bank and a national genetic-testing lab network. The combined company was named LifeWell, and it raised $80 million in a fresh round led by the healthcare investor OrbiMed.

The numbers on each side explain the logic. On MFine’s side: a consumer app with over 6 million users but a loss of ₹205.89 crore in FY22 and shrinking runway. On LifeCell’s side: an established diagnostics and lab business with physical reach — a network described as serving over 3,000 hospitals across 130 cities. MFine brought the demand engine and the software; LifeCell’s diagnostics arm brought the delivery infrastructure and a revenue base that did not depend on burning cash to acquire each user. The $80 million from OrbiMed funded the combined entity rather than propping up the old MFine on its own. In effect, the online-doctor app stopped trying to win on consultations alone and attached itself to the part of healthcare that actually makes money in India: diagnostics.

The money behind it

MFine was well-funded by Indian healthtech standards, raising across four main rounds before the merger. Total capital raised is reported in a range depending on the counter.

• Series A: $4.2 million, May 2018, with Stellaris Venture Partners and Prime Venture Partners.
• Series B: $17.2 million, April 2019, led by Japan’s SBI Investment, with SBI Ven Capital, BEENEXT, Stellaris and Prime Venture Partners.
• Series C: $48 million, September 2021, co-led by Moore Strategic Ventures and BEENEXT, with SBI Group Japan, SBI Ven Capital Singapore, Heritas Capital, Stellaris and Prime Venture Partners.
• Total raised before the merger: reported at about $87.7 million (Tracxn) and up to roughly $97 million by other counts.
• Valuation: reported at about $450 million after the September 2021 Series C. MFine has not confirmed a public figure.

What each backer changed: Prime Venture Partners and Stellaris were the early believers who funded the product; the SBI entities and BEENEXT brought the scale capital and Japanese/Asian networks in the middle rounds; Moore Strategic Ventures and BEENEXT anchored the growth-stage Series C that funded the “virtual hospital” push. After the merger, OrbiMed became the defining investor of the next chapter, leading the $80 million round in 2022 and, in 2024, a further ₹184 crore (about $22 million) pre-IPO round into LifeWell — with OrbiMed putting in ₹150 crore and Cellution Biostorage ₹30 crore, via compulsorily convertible preference shares priced at ₹426.71 each (RoC filing, reported by Indian Startup Times and Entrackr).

How it makes money

MFine’s revenue is a bundle of healthcare transactions and subscriptions layered on top of the consultation. The consultation itself is the cheapest, most competitive product; the money sits downstream of it.

• Consultation fees: paid per teleconsultation, or bundled into a subscription. This is the top of the funnel and the least defensible on price.
• Diagnostics: at-home lab tests and radiology ordered off the back of a consultation. Higher ticket size and repeatable — the strategic core, and the reason the LifeCell diagnostics tie-up made sense.
• E-pharmacy: a margin on medicines dispensed after a prescription.
• Care plans and chronic-care subscriptions: recurring consumer revenue for ongoing management of conditions such as diabetes.
• Corporate subscriptions: employers paying for employee health access, a steadier B2B revenue line.

The part people get wrong: the doctor app is not really where the margin is. Consultations are a customer-acquisition and trust-building step; diagnostics and pharmacy are where a healthtech platform earns. MFine’s FY22 accounts make the cost side plain — advertising was the single largest expense at ₹133.24 crore, so growth was effectively bought, not compounded, until the company cut marketing hard in FY23 (to ₹22.06 crore).

The numbers

Four years of the operating entity, Novocura Tech Health Services, from RoC filings. All figures in ₹ crore.

• FY23 total revenue (including other income) was ₹34.45 crore, down 33.8% from ₹52.06 crore in FY22 — a deliberate contraction as the company stopped buying growth.
• The FY23 loss of ₹86.1 crore was the first meaningful narrowing, roughly 58% lower than FY22, driven by cutting advertising from ₹133.24 crore to ₹22.06 crore and employee costs from ₹62.58 crore to ₹42.87 crore.
• FY22 was the peak of both spend and pain: ₹258 crore of total expenses against about ₹50 crore of operating revenue.

Where the money comes from

MFine has not published an audited segment-by-segment split of revenue, so exact shares by product line are not available and are not estimated here. What the record does show is the direction of travel.

• Consultations were the volume driver and the funnel entry, but the lowest-value transaction.
• Diagnostics was treated as the value layer — the reason the whole business pivoted toward a diagnostics merger rather than doubling down on consultations.
• Geography: the platform was built to extend specialists in metros to patients in smaller cities and towns; the merged entity’s lab network reaches 130 cities (company statement).

The surprise is that the consumer telehealth app, the thing users saw, was the front door, not the profit centre. The 2022 merger was an admission that the durable revenue lived in diagnostics and physical lab infrastructure — the parts of healthcare MFine had not owned.

The risks

• Unit economics of consultations: teleconsultation is a low-margin, high-competition product where customer acquisition is expensive. MFine’s FY22 figure of ₹5.11 spent per rupee earned shows how quickly growth-by-advertising destroys cash if downstream monetisation does not follow.
• Funding dependence: the business was never self-sustaining on its own revenue; each stage relied on the next round. When the 2022 funding winter hit, the model had no cushion, forcing layoffs of more than half the staff and a merger from a position of weakness.
• Integration and identity risk: merging a Bengaluru software-first consumer app into a Chennai diagnostics-and-labs group is an operational and cultural stitch-up. The combined LifeWell has to make a physical, capital-heavy lab network and a light-touch app pull in the same direction, and deliver the growth (50 million users targeted) that justified the $80 million.

The takeaway

MFine’s arc holds one transferable lesson: in healthcare, the customer-facing app is rarely where the money is, and confusing reach with revenue is expensive. MFine built genuine demand — millions of users, a real product, a credible AI triage layer — but the consultation it led with was the least monetisable part of the chain. It spent to win the front door and discovered the profit was three rooms deeper, in diagnostics and pharmacy. The merger was not a failure so much as a correction: the team stopped trying to make the cheap product carry the whole company and attached to the expensive, defensible part of the system. For any platform business, the question is not whether you can acquire users, but whether the thing you acquire them with is the thing you can charge for.

Frequently asked questions

Who founded MFine and when?

MFine was founded in February 2017 in Bengaluru by Ashutosh Lawania and Prasad Kompalli, both of whom came from Myntra. They were joined by other Myntra alumni in senior technology and growth roles.

Did MFine merge with or rebrand to another company?

MFine did not become Licious or any consumer-goods brand. In July 2022 it merged its business with the diagnostics arm of LifeCell International to form a joint venture called LifeWell, which raised $80 million led by OrbiMed. MFine’s consumer app continued to operate under the merged entity.

How much money did MFine raise?

MFine raised across Series A ($4.2 million, 2018), Series B ($17.2 million, 2019) and Series C ($48 million, 2021), for a reported total of about $87.7 million (Tracxn), with some counts putting it near $97 million. The merged entity LifeWell later raised a further $80 million (2022) and about $22 million (2024).

What were MFine’s revenue and losses?

Per RoC filings for Novocura Tech Health Services, operating revenue was ₹12.9 crore in FY21, ₹50.48 crore in FY22 and ₹31.05 crore in FY23. Net loss was ₹102.7 crore in FY21, ₹205.89 crore in FY22 and ₹86.1 crore in FY23.

Why did MFine lay off staff in 2022?

On 21 May 2022, MFine cut more than half its workforce, citing the need to reduce cash burn and extend runway as startup funding tightened. The cuts came about eight months after its $48 million Series C.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42 — “Troubled Healthtech Startup MFine Merges With LifeCell’s Diagnostics Arm, New Entity Raises $80 Mn” (July 2022)
• Inc42 — “Healthtech Startup MFine Raises $48 Mn In Series C Round” (September 2021)
• Entrackr — “mFine spent Rs 258 Cr to make Rs 50 Cr in FY22” (March 2023)
• Entrackr — “Beenext-backed mFine lays off over 50% of its workforce” (May 2022)
• Entrackr — “MFine merges with LifeCell’s diagnostic arm; joint entity raises $80 Mn” (July 2022)
• Indian Startup News — “Healthtech startup mFine revenue drops 33.8% to Rs 34.45Cr in FY23” (2023)
• MobiHealthNews — “Indian mobile health platform MFine merges with biotech company LifeCell’s diagnostic biz” (July 2022)
• BusinessWire / PR Newswire — MFine Series C and Series B funding announcements (2021, 2019)
• VentureBeat — “India’s Mfine raises $17.2 million to expand telemedical doctor network” (April 2019)
• Indian Startup Times — “LifeWell Raises $22 Million Led by OrbiMed” (2024)
• Tracxn — Mfine and Novocura Tech Health Services company profiles (2025-2026)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.